CancerCare Manitoba, Winnipeg: Cancer Care and Patient Guide

CancerCare Manitoba’s roots date to the establishment of the Manitoba Cancer Relief and Research Institute in 1930. It has developed into the provincial agency responsible for cancer services across Manitoba, combining patient care with research, education and cancer control activities.

It is best understood as a provincial organisation rather than one self-contained hospital. Winnipeg is its principal specialist hub, while care also involves partner hospitals and community services. The location of consultations, procedures, admission and follow-up depends on the cancer and treatment plan.

Its scale is reflected in its province-wide remit and community oncology network across rural and northern Manitoba. That network supports selected care closer to home for eligible patients, but complex interventions may still require travel to Winnipeg. It should not be assumed to provide follow-up outside Canada.

The organisation is known for adult oncology, paediatric oncology, blood and marrow transplantation and clinical research. Its public healthcare role is important for visitors to understand: services established for Manitoba residents do not automatically create an accessible or publicly funded treatment route for international patients.

The listed specialities include breast, lung, colorectal and prostate cancers. Assessment in these areas depends on the tumour’s exact diagnosis, stage and, where relevant, molecular characteristics. Patients should ask which disease-specific team would review their case and whether pathology or imaging needs reassessment before treatment recommendations can be made.

Blood cancer services cover conditions such as leukaemia, lymphoma and myeloma, with transplantation relevant to selected diagnoses and disease stages. The blood and marrow transplant programme is a notable component of the organisation’s specialist care, but transplantation is not appropriate for every blood cancer.

Paediatric oncology provides a separate pathway for children with cancer. Families should confirm age criteria, the relevant hospital setting and arrangements for caregiver participation. Decisions about childhood cancers and transplantation require assessment by the appropriate specialist team rather than reliance on a general service listing.

Surgery may form part of treatment for solid tumours, including breast, lung, colorectal and prostate cancers. In Manitoba’s care system, operations involve the relevant surgical and hospital teams. An international patient should establish whether acceptance for an oncology consultation also includes access to surgery, anaesthesia, inpatient care and postoperative review.

Radiation therapy is an important treatment modality. Its suitability, treatment area and schedule depend on diagnosis, previous radiation exposure and the purpose of care. Patients previously treated elsewhere may need to supply detailed radiation plans and dose records so clinicians can assess whether further treatment is feasible.

Systemic treatment options include chemotherapy, immunotherapy and targeted therapy. These are not interchangeable: selection can depend on pathology, biomarkers, previous treatments, organ function and general health. A medicine’s use in another country does not establish that it is available, funded or clinically appropriate in Manitoba. Testing and drug access should be clarified individually.

Stem cell transplantation is available through the blood and marrow transplant programme for selected patients. Assessment can involve disease status, fitness, donor considerations and the ability to remain near specialist care. Transplantation may require lengthy monitoring and substantial caregiver support. Patients should request a complete pathway covering preparation, admission, complications and follow-up, not simply confirmation that the procedure is offered.

The supplied profile describes around 80 active oncology clinical trials. This figure is indicative and can change as studies open, close or move into follow-up. An active study is not necessarily recruiting, and a broad portfolio does not mean there is a suitable trial for every cancer type or treatment stage.

Trial eligibility commonly depends on the precise diagnosis, biomarkers, previous therapy, measurable disease, laboratory results and functional status. International patients should ask whether a relevant study is currently recruiting at CancerCare Manitoba and whether non-resident participation is possible. A clinician may need to review records before any preliminary assessment can be offered.

Trial participation requires informed consent and protocol-specific screening; acceptance cannot be guaranteed in advance. Patients should clarify which research procedures are funded and which routine care, travel or complication-related expenses remain their responsibility. Repeated visits and follow-up requirements may make participation impractical for someone living abroad.

Before travelling, seek confirmation of the referral route, whether international referrals are accepted and which team would assess the case. Ask whether records can be reviewed before an in-person visit and what that review can establish. A preliminary opinion is different from an agreed treatment plan or a reserved treatment date. Funding and any required payment arrangements should be clarified separately from clinical suitability.

Plan for the whole episode of care, including diagnostic reassessment, possible admission, recovery and return-home monitoring. Confirm travel documentation, suitable insurance and accommodation only after the care pathway is clear. Patients considering intensive treatment should ask about caregiver requirements and restrictions on flying. Arrange communication with the home oncology team and establish who will manage urgent problems and ongoing medicines after departure.

Contact details below come from the hospital's own published international patient information.

Location: Winnipeg, Canada

Email: No public international e-mail address is published; use the website enquiry form.

Phone: +1 204 787 2197

Website: https://www.cancercare.mb.ca

Languages supported: English, French

Remote second opinion: Not advertised

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.